Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugsHospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
SUBMITTED BY PGMCINTOSH ON TUE, 04/09/2012 - 11:39
A study by the SDRN Epidemiology Group.
Aims/hypothesis
Current drug labels for thiazolidinediones (TZDs) warn of increased fractures, predominantly for distal fractures in women. We examined whether exposure to TZDs affects hip fracture in women and men and compared the risk to that found with other drugs used in diabetes.
Tags: Epidemiology
Read more